Report

TheraCryf | Patent protection potentially extending to 2046

TheraCryf has announced the filing of a new manufacturing process patent covering the production of its lead Ox-1 asset which is on track for clinical trial readiness by the end of this year. When granted, the patent should extend TheraCryf's effective period of exclusivity for Ox-1 to 2046, materially beyond existing patent protection through 2038/39 covering the US, Europe and China. That additional protection, should enhance the commercial attractiveness of Ox-1 significantly, likely further increasing partnering and acquisition interest.
Underlying
Evgen Pharma

Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.

Provider
Capital Access Group
Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Analysts
Colin Smith

Other Reports on these Companies
Other Reports from Capital Access Group

ResearchPool Subscriptions

Get the most out of your insights

Get in touch